Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship

NCT04274283 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT04274283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
Lead sponsor
University of Birmingham
Phase
Observational
Overall status
Recruiting
Start date
November 24, 2020
Completion date
February 29, 2028
Enrollment
1,000 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

glioma